FIELD: chemistry, pharmaceutics.
SUBSTANCE: invention relates to method of treating proliferative disease in subject, including introduction to subject of (a) therapeutically effective quantity of AC220 or its salt in dose from approximately 27 to 1000 mg/day, and of (b) second agent, selected from azacitidine, cytarabinum, etoposide, daunorubicin, cladribine, where azacitidine is introduced in dose 50-100 mg/m2/day, cytarabinum is introduced in dose from 5 mg/m2/day to 3 mg/m2/day, etoposide is introduced in dose 10-150 mg/m2/day and daunorubicin is introduced is dose 10-60 mg/m2/day.
EFFECT: invention makes it possible to extend arsenal of medications for treating proliferative diseases, including cancer.
39 cl, 10 dwg, 26 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF APPLYING (+)-1,4-DIHYDRO-7-[(3S, 4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(THIAZOLYL)-1,8-NAPHTHIRIDINE-3-CARBOXYLIC ACID FOR CANCER TREATMENT | 2006 |
|
RU2592231C2 |
| METHODS OF APPLYING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THUASOLYL)-1,8-NAPHTHYDIRINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER | 2006 |
|
RU2428983C2 |
| PHORBOL ESTER COMPOSITIONS AND METHODS OF USING THEM FOR TREATING OR REDUCING DURATION OF CYTOPENIA | 2015 |
|
RU2730998C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| COMBINED THERAPY FOR TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASTIC SYNDROME | 2002 |
|
RU2338535C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATED WITH LSD1, LSD1 INHIBITORS | 2020 |
|
RU2826217C1 |
| PHOSPHORAMIDATE ALKYLATOR PRODRUG | 2006 |
|
RU2414475C2 |
